Ascendis Pharma A (ASND) Return on Sales (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Return on Sales data on file, last reported at 0.03% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales rose 3.0% year-over-year to 0.03%; the trailing twelve-month figure through Mar 2026 stood at 0.01% (up 1.0% YoY), and the FY2025 full-year result was 0.0%, up 1.0% from the prior year.
• Return on Sales improved to 0.03% in Q1 2026, from 0.0% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.03% in Q1 2026 to a low of 0.18% in Q1 2022.
• A 5-year average of 0.04% and a median of 0.02% in 2024 frame the typical range for Return on Sales.
• Peak annual rise in Return on Sales reached 118 bps in 2022, while the deepest fall reached 7 bps in 2022.
• Tracing ASND's Return on Sales over 5 years: stood at 0.09% in 2022, then surged by 97 bps to 0.0% in 2023, then jumped by 53 bps to 0.0% in 2024, then jumped by 59 bps to 0.0% in 2025, then soared by 5455 bps to 0.03% in 2026.
• Business Quant data shows ASND's Return on Sales at 0.03% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.